ɅIKIUM Inc.
The SeqR™ Protein Therapeutics Co.
Powered by Yotta-ML²™ - the AI + Synthetic Biology Platform
Aikium Inc. is developing therapeutics for neuro-inflammation and oncology, targeting multi-pass membrane protein targets beyond the reach of traditional antibody-based approaches
Our proprietary non-antibody scaffold protein — the SeqR (“seeker”), seeks and binds to disordered regions of target proteins in a sequence-specific manner
Yotta-ML² is the platform that enables Yotta (10²⁴) - scale machine learning (ML) on massive libraries (ML) of proteins
Scientific Advisory Board
-
![]()
Prof. George Church
Harvard, MIT, Wyss
-
![]()
Dr. Kevin Yang
DEEP LEARNING FOR PROTEINS EXPERT
Microsoft Research
-
![]()
Dr. Mark Lebwohl
Mt. Sinai, New York
-
![]()
Dr. Nicolas Gaudenzio
INSERM, Genoskin
-
![]()
Dr. Mette Rosenkilde
Univ. of Copenhagen, Bainan, Synklino, Antag Tx
-
![]()
Prof. Lawrence Stern
U Mass Med School, MIT
-
![]()
Dr. Tarjei Mikkelsen
CTO, Arsenal Bio
Founders
Aikium beckons!
Be a part of the foundational team that is working on a field-defining technology, and enable a path to 100 therapies within a decade
Partner with us
We are ready to take on pilot projects involving your targets!
